SENZA SenzaGen AB (publ)
SenzaGen AB (publ) provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries. Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB (publ) was incorporated in 2010 and is headquartered in Lund, Sweden.…
Industry Peers
Diagnostics & ResearchKey Statistics
About SenzaGen (STO: SENZA)
›
SenzaGen (STO: SENZA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 4.490 SEK on 19 November 2026, down 27.8% over 52 weeks. Its 52-week range is 4.210 SEK to 6.700 SEK: the price is 33.0% below the high and 6.7% above the low.
Its market capitalisation is 145.96M SEK.
SenzaGen reports return on equity of -14.9%, an operating margin of -10.4% and revenue up 6.8% year over year.
It holds more cash than debt, a net cash position of 16.97M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.